---
title: "Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation"
id: "medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1?rss=1"
published_at: "2026-09-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1?rss=1)
- **Published At:** 2026-09-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective diagnostic model-development and internal validation study used 1,199 histopathology-verified dermoscopic images (578 benign, 621 malignant) drawn from an initial ISIC Archive screen of 552,869 records. - The authors developed an ensemble that fuses ImageNet-pretrained **EfficientNetB0** and **Swin-T (Swin Transformer Tiny)** features to classify lesions as benign melanocytic lesions or malignant **melanoma**. - Patient-independent five-fold validation was performed with weighted sampling, mixup, label smoothing, AdamW optimization, early stopping, and five-view test-time augmentation to reduce overfitting and data leakage. - Reported mean performance: accuracy 0.89325 ± 0.03179, ROC-AUC 0.96348 ± 0.01695, and support-weighted F1-score 0.89300 ± 0.03220. Fold-level 95% CIs: accuracy 0.8538–0.9327, ROC-AUC 0.9424–0.9845. - Pooled confusion counts: 526 true negatives, 52 false positives, 76 false negatives, 545 true positives; sensitivity 87.76% and specificity 91.00% were calculated from these pooled counts. - Explainability checks used qualitative **Grad-CAM** review; peripheral artifact activation was observed in two false positives and lesion-centered activation in two true positives, but interpretability findings were not scored systematically. - Limitations explicitly reported: use of validation folds for early stopping/checkpoint selection, absence of device-stratified analysis, no systematic interpretability scoring, no calibration assessment, and lack of independent external validation. - Data availability: source images and metadata are public via the ISIC Archive; the filtered 1,199-image cohort manifest and metadata are available from the corresponding author on reasonable request and per ISIC terms. - Authors emphasize the ensemble is intended only as a clinician-facing adjunct and that external validation is required before clinical use or claims of generalizability.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=ozQv11B9mTaFGR0mNvN0tBRkc5tZ9NlzygNbvjDACDM-1788625420.31065-1.2.1.1-mnxLHk4t.jL0IqsNLqZoLXk8CYZmjdk18Bx6yJ2YWZrAzvwJdoeXEIJwUoEDkDm.) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Skin Cancer Classification Using Explainable Artificial Intelligence With an Ensemble Model and Rigorous Leakage Free Validation [ View ORCID Profile](http://orcid.org/0000-0003-3796-9950)MEHMET TARIK BARAN, [ View ORCID Profile](http://orcid.org/0009-0008-8196-7470)OMER KARAKOYUN doi: https://doi.org/10.64898/2026.09.02.26362011 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. MEHMET TARIK BARAN 1 Mardin Artuklu University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=MEHMET%2BTARIK%2BBARAN%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=BARAN%20MT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMEHMET%2BTARIK%2BBARAN%2B) * [ORCID record for MEHMET TARIK BARAN](http://orcid.org/0000-0003-3796-9950 "Open in new tab") * For correspondence: mtarikbaran@artuklu.edu.tr OMER KARAKOYUN 2 GAZI YASARGIL EDUCATION AND TRAINING HOSPITAL * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=OMER%2BKARAKOYUN%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=KARAKOYUN%20O&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AOMER%2BKARAKOYUN%2B) * [ORCID record for OMER KARAKOYUN](http://orcid.org/0009-0008-8196-7470 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1293552/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1293552/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1293552/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1293552/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1293552/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1293552/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Reliable melanoma classification requires models that capture both local dermoscopic morphology and broader contextual patterns while maintaining auditable, leakageaware internal validation. Objectives: To develop and internally validate an EfficientNetB0-Swin Transformer Tiny ensemble for classifying histopathologically verified dermoscopic images as benign melanocytic lesions or malignant melanoma. Methods: This retrospective diagnostic model-development and internal validation study screened 552,869 ISIC Archive records; filtering and dermatologist review yielded 1,199 uniquepatient and unique lesion images (578 benign and 621 malignant). Images were the predictors and histopathology was the reference. ImageNet pretrained EfficientNetB0 and Swin-T features were fused. Patient independent five fold validation used weighted sampling, mixup, label smoothing, AdamW, early stopping, and five view test time augmentation. Results: Mean accuracy was 0.89325 ± 0.03179, mean receiver operating characteristic area under the curve (ROC-AUC) was 0.96348 ± 0.01695, and mean support weighted F1-score was 0.89300 ± 0.03220. The fold level 95% confidence intervals were 0.8538-0.9327 for accuracy and 0.9424-0.9845 for ROC-AUC. Pooled counts were 526 true negatives, 52 false positives, 76 false negatives, and 545 true positives, yielding 87.76% sensitivity and 91.00% specificity. Qualitative Grad-CAM review showed peripheral artifact activation in two false positives and lesion centered activation in two correctly classified cases; these observations were not systematically scored. Limitations: The validation folds were also used for early stopping and checkpoint selection. Device stratified analysis, systematic interpretability scoring, calibration, and independent external validation were unavailable. Conclusions: The ensemble showed high internal discrimination and is intended only as a clinician facing adjunct. The error audit workflow enables targeted retrospective review, but external validation is required before clinical use or generalizability claims. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: International Skin Imaging Collaboration (ISIC) Archive: https://www.isic-archive.com/ I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The source images and metadata are publicly available through the International Skin Imaging Collaboration Archive (https://www.isic-archive.com/). Individual images remain subject to the license and attribution requirements attached to each ISIC record. The filtered 1,199-image cohort manifest, applied query criteria, and associated metadata supporting the findings of this study are available from the corresponding author upon reasonable request and subject to the applicable ISIC terms of use. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.02.26362017v1 "A Time-Dependent Diffusion MRI Framework for Clinical Characterisation of Human Brain Cellular Architecture")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.02.26361629v1 "Pupil symmetry and Swinging Light Test Performed with VR Headset for Detection of Anisocoria and Relative Afferent Pupillary Defect") Posted September 05, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/05/2026.09.02.26362011.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.02.26362011v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/05/2026.09.02.26362011.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Skin Cancer Classification Using Explainable Artificial Intelligence With an Ensemble Model and Rigorous Leakage Free Validation MEHMET TARIK BARAN, OMER KARAKOYUN medRxiv 2026.09.02.26362011; doi: https://doi.org/10.64898/2026.09.02.26362011 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362011v1%26text%3DSkin%2520Cancer%2520Classification%2520Using%2520Explainable%2520Artificial%2520Intelligence%2520With%2520an%2520Ensemble%2520Model%2520and%2520Rigorous%2520Leakage%2520Free%2520Validation "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362011v1%26t%3DSkin%2520Cancer%2520Classification%2520Using%2520Explainable%2520Artificial%2520Intelligence%2520With%2520an%2520Ensemble%2520Model%2520and%2520Rigorous%2520Leakage%2520Free%2520Validation "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362011v1%26title%3DSkin%2520Cancer%2520Classification%2520Using%2520Explainable%2520Artificial%2520Intelligence%2520With%2520an%2520Ensemble%2520Model%2520and%2520Rigorous%2520Leakage%2520Free%2520Validation%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362011v1%26title%3DSkin%2520Cancer%2520Classification%2520Using%2520Explainable%2520Artificial%2520Intelligence%2520With%2520an%2520Ensemble%2520Model%2520and%2520Rigorous%2520Leakage%2520Free%2520Validation "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.02.26362011) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.02.26362011v1&count=horizontal&via=&text=Skin%20Cancer%20Classification%20Using%20Explainable%20Artificial%20Intelligence%20With%20an%20Ensemble%20Model%20and%20Rigorous%20Leakage%20Free%20Validation&counturl=www.medrxiv.org/content/10.64898/2026.09.02.26362011v1 "Tweet This") ## Subject Area * [Health Systems and Quality Improvement ](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (615) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (897) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (327) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4778) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (476) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (410) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (645) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1617) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15857) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1196) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6999) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (728) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1059) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5002) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1429) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1743) * [Hematology](https://www.medrxiv.org/collection/hematology) (583) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1338) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16255) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1163) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (665) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (721) * [Neurology](https://www.medrxiv.org/collection/neurology) (7211) * [Nursing](https://www.medrxiv.org/collection/nursing) (365) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1234) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1002) * [Oncology](https://www.medrxiv.org/collection/oncology) (3581) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1039) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (394) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (448) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (466) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (704) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1782) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5849) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9706) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2394) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1436) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1245) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (635) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (769) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (577) * [Surgery](https://www.medrxiv.org/collection/surgery) (770) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (303) * [Urology](https://www.medrxiv.org/collection/urology) (288) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Community reviews for this article: _There are no community reviews for this paper._ Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Automated Evaluations: _There are no automated evaluations for this paper._ Blog/Media Links medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's
## Related Clinical Research

- [FDA approves first targeted pancreatic cancer drug; Trump administration strikes biotech drug-pric](https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump.md)
- [Moderna–Merck cancer vaccine and the role of the algorithm behind its mRNA design](https://medichelpline.com/clinical-feed/stat-news-1-stat-the-mystery-of-moderna-s-magic-algorithm.md)
- [State Tanning Bed Availability Linked to Higher Early-Onset Melanoma in Midwest and South](https://medichelpline.com/clinical-feed/medrxiv-1-state-tanning-bed-availability-is-associated-with-early-onset-melanoma.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Shared IRF4/HERC2 Variants in Uveal and Cutaneous Melanoma: Bioinformatic Evidence and Prognostic](https://medichelpline.com/clinical-feed/medrxiv-16-uveal-and-cutaneous-melanoma-share-a-common-mutation-with-distinct-prognostic.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.